MedPath

Treatment of Central Obesity with Unani Medicine Jawarish-e-Bisbasa.

Phase 2
Conditions
Health Condition 1: E668- Other obesityHealth Condition 2: null- Saman e Mufrit (Central Obesity)
Registration Number
CTRI/2018/08/015404
Lead Sponsor
Central Council for Research in Unani Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Patients of Saman Mufrit (Central Obesity) presenting with the following:

1 BMI Male equal to or less than 34.99 kg/m2 and Female equal to or less than 32.49 kg/m2)

2 Waist Circumference (more than 94cms in Males and more than 80 cms in Females)

3 Waist â?? to â?? hip ratio between (more than 80cm to less than 1m), (Female 80 to 85 and male more than 90cm to less than 1m)

4 Saggital Abdominal Diameter (SAD) more than 25 cms

5 Patients presenting with central obesity with or without following complaints:

I.Heart burn

II.Fullness of stomach

III.Breathing difficulties

IV.Sleep apnea

Exclusion Criteria

1.Medications causing secondary weight gain e.g.Phenothiazines, sodium valproate, carbamazepine, lithium, glucocorticoids, thiazolidinedioneâ??s, sulphonylureas, adrenergic antagonists, etc

2.Patient on Oral contraceptive pills or Hormone Replacement therapy

3.Patient having systemic illness requiring long term treatment

4.Patients unable to exercise

5.Pregnant and lactating females

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Improvement in sign and symptoms of Saman e Mufrit (Central Obesity)Timepoint: 8 weeks
Secondary Outcome Measures
NameTimeMethod
Hematological and biochemical assessments for safetyTimepoint: 8 weeks
© Copyright 2025. All Rights Reserved by MedPath